Proteomics International Laboratories Ltd. (PIQ) AI Stock Analysis

• Market Cap: AU$52.86M
• Dividend Yield: N/A
• Average Volume (3M): 426.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: 7.65%
• EPS Growth: -19.13%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 165,184,000
• 10 Day Avg. Volume: 295,611
• 30 Day Avg. Volume: 426,904
• PEG Ratio: -0.84
• Price to Book (P/B): 3.69
• Price to Sales (P/S): 50.61
• P/FCF Ratio: -7.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.43
• Price Target Upside: -35.82% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: AU$0.30 ▼(-55.07% Downside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily weighed down by weak financial performance (steep revenue decline, ongoing losses, and negative operating/free cash flow). Technicals also remain bearish with the price below key moving averages, while oversold readings provide only a modest offset. Valuation is hard to support because the negative P/E reflects unprofitable operations and no dividend data is available.

Positive Factors

Low Leverage

A very low debt-to-equity ratio (0.021) gives the company durable financial flexibility, lowering default and refinancing risk. This supports continued R&D and commercialization spending without large interest burdens, preserving strategic optionality over the next 2-6 months.

Diversified Revenue Model

Revenue split between diagnostic product/testing and fee-for-service proteomics gives structural resilience. Contract lab work generates repeatable fee income while diagnostics offer scale and licensing upside, reducing reliance on a single revenue source long-term.

Positive Gross Margin

A positive gross margin indicates the core testing and services can be economically viable if fixed operating costs are controlled. This provides a pathway to profitability once sales scale or operating expenses are managed, supporting medium-term margin recovery.

Negative Factors

Steep Revenue Decline

A ~72% revenue collapse signals loss of customers, lower test volumes or commercialization setbacks. Such structural top-line deterioration undermines scale economics, lengthens the runway to break-even and makes investment in commercialization riskier over months ahead.

Sustained Operating Losses

Persistent negative EBIT and net margins show operations do not yet cover overhead and R&D. Continued losses erode equity and constrain reinvestment, making the business dependent on external funding or rapid revenue recovery to sustain operations over the medium term.

Negative Operating Cash Flow

Negative operating and free cash flow indicate cash burn from core activities. Even with some alignment between FCF and net income, ongoing outflows limit liquidity, increase financing risk, and pressure management to cut costs or raise capital within the next several months.

Proteomics International Laboratories Ltd. Business Overview & Revenue Model

Company Description

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.

How the Company Makes Money

PIQ generates revenue through several key streams, including contract research services for pharmaceutical and biotechnology companies, which involve bespoke proteomic analyses and biomarker validations. Additionally, the company offers diagnostic testing services, particularly in the fields of cancer and other diseases, which contribute to its earnings. Partnerships with academic institutions and research organizations enhance PIQ's capabilities and extend its market reach, while potential licensing agreements for proprietary technologies may further augment its revenue. The company's focus on advancing personalized medicine also positions it strategically to capitalize on emerging trends within the healthcare industry.

Proteomics International Laboratories Ltd. Financial Statement Overview

Summary

Overall financials are weak: sharp revenue decline (-72.53%), ongoing losses (negative net and EBIT margins), and negative operating/free cash flow. Low leverage (debt-to-equity 0.021) is a key offset, but negative ROE and cash burn keep the score low.

Income Statement

Proteomics International Laboratories Ltd. has experienced significant revenue decline, with a revenue growth rate of -72.53% in the latest year. The company is operating at a loss, as indicated by negative net profit margins (-8.45%) and EBIT margins (-11.06%). The gross profit margin is positive, but the overall profitability is weak due to high operating expenses.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.021, indicating minimal leverage, which is a positive aspect. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is relatively stable, suggesting a solid asset base compared to liabilities.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash outflows from operations. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with net income, but overall cash flow health is weak due to consistent negative operating cash flows.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	480.45K	960.39K	892.14K	730.34K	1.49M	1.31M
Gross Profit	-9.26M	960.39K	-1.12M	-1.62M	-568.62K	497.08K
EBITDA	-11.94M	-10.00M	-8.40M	-7.55M	-4.56M	-2.77M
Net Income	-9.66M	-8.11M	-6.38M	-6.23M	-4.97M	-2.86M
Balance Sheet
Total Assets	11.30M	14.78M	10.88M	10.08M	5.40M	8.60M
Cash, Cash Equivalents and Short-Term Investments	7.67M	11.04M	6.64M	6.03M	2.11M	5.60M
Total Debt	681.45K	277.74K	316.39K	64.09K	0.00	69.05K
Total Liabilities	4.09M	1.81M	1.63M	1.75M	2.00M	990.19K
Stockholders Equity	7.45M	13.17M	9.41M	8.38M	3.39M	7.61M
Cash Flow
Free Cash Flow	-8.41M	-6.63M	-6.00M	-6.91M	-3.67M	-2.41M
Operating Cash Flow	-6.35M	-6.60M	-5.59M	-5.69M	-3.54M	-2.21M
Investing Cash Flow	-2.07M	-29.65K	-388.02K	-1.17M	-129.46K	-191.00K
Financing Cash Flow	10.76M	11.03M	6.59M	10.77M	176.10K	5.64M

Proteomics International Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PIQ, the sentiment is Negative. The current price of 0.67 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.54, and above the 200-day MA of 0.41, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 24.45 is Positive, neither overbought nor oversold. The STOCH value of 19.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PIQ.

Proteomics International Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RAD	55 Neutral	AU$74.43M	-0.82	-100.67%	―	1114.27%	85.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PTX	50 Neutral	AU$66.25M	-5.28	-49.72%	―	―	10.78%
CHM	45 Neutral	AU$8.84M	-0.15	-469.35%	―	―	46.28%
NUZ	42 Neutral	AU$57.99M	-4.29	-247.98%	―	―	―
PIQ	41 Neutral	AU$52.86M	-4.45	-71.87%	―	7.65%	-19.13%
RCE	41 Neutral	AU$130.13M	-2.84	―	―	―	0.66%

Proteomics International Laboratories Ltd. Corporate Events

Proteomics International Widens Half-Year Loss as Revenue Declines

Proteomics International Laboratories reported a weak first half for the six months to 31 December 2025, with operating and other activity revenues falling 30% to $357,000 and total income including grants and other revenue declining 10% to $868,749. The company’s net loss attributable to members widened by 34% to $6.03 million, though net tangible asset backing per share improved to 4.4 cents from 4.0 cents, signalling continued balance sheet support despite mounting losses and the absence of any dividend.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.38 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Founder Dr Richard Lipscombe Retires from Board

Proteomics International Laboratories Ltd announced the formal retirement of founder and Managing Director Dr Richard Lipscombe from its board of directors, effective 23 February 2026, after 25 years of leadership. His departure marks the end of a tenure in which he was credited with establishing the company as a global leader in precision diagnostics, signalling a significant leadership transition that may shape the company’s next phase of strategic development.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.38 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Seeks ASX Quotation for Additional 67,566 Shares

Proteomics International Laboratories Ltd has applied to the ASX for quotation of 67,566 new fully paid ordinary shares under its code PIQ, with an issue date of 2 February 2026. The additional securities arise from the exercise or conversion of existing options or other convertible securities, modestly increasing the company’s quoted share capital and signaling incremental shareholder participation without indicating a broader capital-raising or strategic shift in this announcement.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.47 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Seeks ASX Quotation for 1.16m New Shares

Proteomics International Laboratories Ltd has applied to the ASX for quotation of 1,164,320 new ordinary fully paid shares, to be issued on 21 January 2026 under its ticker PIQ. The additional securities, arising from the exercise or conversion of existing instruments, modestly expand the company’s quoted capital base, potentially enhancing liquidity for shareholders and supporting ongoing corporate and operational funding needs.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.74 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Appoints David Morris to Board With No Initial Shareholding

Proteomics International Laboratories Ltd has appointed David Morris as a director effective 19 January 2026, according to an initial director’s interest notice lodged with the ASX. The filing confirms that Morris currently holds no relevant interests in the company’s securities and has no disclosed interests in related contracts, indicating a board-level change without immediate implications for the company’s capital structure or ownership dynamics.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.74 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Wins Canadian Patent for PromarkerEso Esophageal Cancer Test

Proteomics International Laboratories has secured a Canadian patent for PromarkerEso, its first-in-class blood test designed for the early diagnosis of esophageal adenocarcinoma, extending intellectual property protection for the test in Canada until November 2035. The patent strengthens the company’s commercialisation pathway in North America by supporting potential direct sales, partnerships and licensing, and complements existing protection in Australia, China, Hong Kong, Europe and the US. Given that esophageal adenocarcinoma is frequently linked to chronic acid reflux, has poor survival rates and is often diagnosed late due to reliance on invasive and costly endoscopy, the company positions PromarkerEso as a highly accurate, less invasive screening tool that could meet a significant unmet clinical need and support its growth in global diagnostics markets.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.84 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Seeks ASX Quotation for 147,286 New Shares

Proteomics International Laboratories Ltd has applied to the ASX for quotation of 147,286 new fully paid ordinary shares under its ticker PIQ, effective 16 January 2026. The incremental issuance modestly expands the company’s listed share capital, potentially enhancing liquidity in its stock and reflecting ongoing exercise or conversion of existing securities by investors.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.84 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Names David Morris CEO to Lead Global Commercial Push

Proteomics International Laboratories has appointed David Morris as Chief Executive Officer and Managing Director, effective 19 January 2026, marking a leadership transition from founder Dr Richard Lipscombe, who retires after 25 years but will assist during a handover period. Morris, a seasoned healthcare and medtech executive with experience at Cochlear, Nanosonics, Polynovo and Monash IVF, is being brought in to drive commercial execution and international market penetration of the company’s Promarker diagnostic pipeline, with a remuneration package heavily weighted to performance-based short- and long-term incentives, underscoring the board’s focus on translating its precision diagnostic technology into global commercial growth for patients and shareholders.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.63 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Seeks ASX Quotation for Additional 32,430 Shares

Proteomics International Laboratories Ltd has lodged an application with the ASX for quotation of 32,430 new ordinary fully paid shares under the code PIQ. The additional securities arise from the exercise or conversion of existing options or other convertible securities, slightly increasing the company’s quoted share capital and potentially broadening its investor base, though the modest size of the issue suggests minimal immediate dilution for existing shareholders.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.63 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Announces Lapse of 15,072 Employee Performance Rights

Proteomics International Laboratories Ltd has notified the market that 15,072 employee performance rights (ASX code: PIQAY) have lapsed as of 31 December 2025 because the conditions attached to those rights were not met or became incapable of being satisfied. The cessation modestly reduces the company’s potential future issued capital under its employee incentive arrangements but does not involve any new capital raising or change to existing listed securities, indicating a routine adjustment to its share-based remuneration structure.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.63 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Wins CAP Accreditation, Commissions US Mass Spec Lab for Promarker Tests

Proteomics International Laboratories has strengthened its US footprint after its Irvine, California reference laboratory secured accreditation from the College of American Pathologists, a quality benchmark regarded as the gold standard and more demanding than existing CLIA certification. Alongside the accreditation, the company has commissioned a new mass spectrometry platform to support commercialisation of its Promarker suite of precision diagnostic blood tests, initially focusing on establishing the PromarkerEso assay for esophageal adenocarcinoma ahead of a planned US launch in 2026, while also positioning the facility to run future tests such as PromarkerEndo for endometriosis, reinforcing Proteomics International’s positioning as a leading provider of high-quality precision diagnostics.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

PromarkerD Test Enhances Diabetic Kidney Disease Management in Australia

Proteomics International Laboratories Ltd announced the publication of a peer-reviewed study in the Internal Medicine Journal, demonstrating the clinical utility of their PromarkerD test in Australia. The study showed that PromarkerD significantly influences clinical decision-making by prompting earlier initiation of renoprotective therapies and reducing the use of nephrotoxic drugs among patients at risk of diabetic kidney disease. With 89% of surveyed physicians believing in the test’s potential to improve clinical outcomes, the findings support PromarkerD’s role in enhancing treatment strategies for the 1.5 million Australians with type 2 diabetes, potentially leading to better patient management and reduced healthcare costs.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.

Proteomics International Launches Precision Diagnostics Services

Proteomics International Laboratories Ltd has announced the commercial launch of its precision diagnostics services, marking a significant milestone in the company’s operations. This move is expected to enhance the company’s market positioning in the healthcare sector, potentially offering new opportunities for growth and development, and providing stakeholders with insights into the company’s future trajectory.

The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.